Table 2 Treatment delivery

From: UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial

Cycle of treatment

<75 years ( n =23)

75 years ( n =21)

Total ( n =44)

1

23 (100%)

21(100%)

44 (100%)

2

21 (91%)

18 (86%)

39 (89%)

3

12 (52%)

14 (67%)

26 (59%)

4

9 (39%)

11 (52%)

20 (45%)

5

6 (26%)

10 (48%)

16 (36%)

No. of cycles

   

 Median

3

4

3

 Range

1–18

1–16

1–18